1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JAN-2022.

01/12/2022 EDT

Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JAN-2022. These Common Stock will be under lockup for 181 days starting from 15-JUL-2021 to 12-JAN-2022. Details: The directors and executive officers, and substantially all the securityholders have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not and may not cause any of their direct or indirect affiliates to, without the prior written consent of J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BofA Securities, Inc., offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up securities, whether any such transaction to be settled by delivery of the lock-up securities, in cash or otherwise make any demand for or exercise any right with respect to the registration of any the lock up securities, or publicly disclose the intention to do any of the foregoing.

© S&P Capital IQ 2022
All news about ERASCA, INC.
05/25Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
05/25Erasca, Inc. Announces Key Appointments
05/12Erasca Narrows Q1 Loss, Misses Street Estimates
05/12ERASCA, INC. Management's Discussion and Analysis of Financial Condition and Results o..
05/12Earnings Flash (ERAS) ERASCA Reports Q1 Loss $-0.31
05/12Erasca Reports First Quarter 2022 Financial Results and Business Updates
05/12Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
05/03Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
04/27ERASCA, INC. : Change in Directors or Principal Officers (form 8-K)
04/27Erasca Appoints Jean Liu to its Board of Directors
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -161 M - -
Net cash 2022 275 M - -
P/E ratio 2022 -4,31x
Yield 2022 -
Capitalization 684 M 684 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 123
Free-Float 79,8%
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 5,61 $
Average target price 21,60 $
Spread / Average Target 285%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Les Brail VP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-63.99%684
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026